Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.64 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.61 |
| ▸ | MAOA | P21397 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 2/20 | 0.58 |
| ▸ | MIF | P14174 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.49 |
| ▸ | METAP1 | P53582 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17571252 | 1.00 | MAOB (0.64) | MAOBCYP19A1MAOAALDH1A1SMN1; SMN2 | |
| SCHEMBL6990658 | 1.00 | MAOB (0.64) | MAOBCYP19A1MAOAALDH1A1SMN1; SMN2 | |
| SCHEMBL29946409 | 0.90 | MIF (0.63) | CYP19A1ALDH1A1SMN1; SMN2NPC1LMNA | |
| SCHEMBL7001016 | 0.90 | MIF (0.63) | CYP19A1ALDH1A1SMN1; SMN2NPC1LMNA | |
| SCHEMBL30938680 | 0.90 | MIF (0.63) | CYP19A1ALDH1A1SMN1; SMN2NPC1LMNA | |
| SCHEMBL7001015 | 0.90 | MIF (0.63) | CYP19A1ALDH1A1SMN1; SMN2NPC1LMNA | |
| SCHEMBL6361474 | 0.82 | MAOB (0.67) | MAOBCYP19A1MAOAALDH1A1SMN1; SMN2 | |
| SCHEMBL7510755 | 0.82 | MAOB (0.67) | MAOBCYP19A1MAOAALDH1A1SMN1; SMN2 | |
| SCHEMBL6361472 | 0.82 | MAOB (0.67) | MAOBCYP19A1MAOAALDH1A1SMN1; SMN2 | |
| SCHEMBL7238871 | 0.81 | KDM4E (0.46) | MAOBCYP19A1ALDH1A1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323043-B2 | Derivatives of macrocyclic N-aryl-tricyclopyrimidine-2-amine polyethers as inhibitors of FTL3 and JAK | PIERRE FABRE MEDICAMENT (FR) | 2019-06-18 | — | — | US | disclosed |
| US-20170283432-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-TRICYCLOPYRIMIDINE-2-AMINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | PIERRE FABRE MEDICAMENT (FR) | 2017-10-05 | — | — | US | disclosed |
| EP-0989985-B1 | FUSED POLYCYCLIC 2-AMINOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CELLTECH THERAPEUTICS LTD (GB) | 2003-11-05 | — | — | EP | disclosed |
| US-6599908-B1 | Potent and selective inhibitors of the protein tyrosine kinases p56lck and p59fyn | CELLTECH R & D LIMITED (GB) | 2003-07-29 | — | — | US | disclosed |
| US-6133257-A | Fused polycyclic 2-aminopyrimidine derivatives | CELLTECH THERAPEUTICS LIMITED (GB) | 2000-10-17 | — | — | US | disclosed |
| US-6057329-A | Fused polycyclic 2-aminopyrimidine derivatives | CELLTECH THERAPEUTICS LIMITED (GB) | 2000-05-02 | — | — | US | disclosed |
| EP-0989985-A1 | FUSED POLYCYCLIC 2-AMINOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 2000-04-05 | — | — | EP | disclosed |
| EP-0946523-A1 | FUSED POLYCYCLIC 2-AMINOPYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PROTEIN TYROSINE KINASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998058926-A1 | FUSED POLYCYCLIC 2-AMINOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1998-12-30 | — | — | WO | disclosed |
| WO-1998028281-A1 | FUSED POLYCYCLIC 2-AMINOPYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PROTEIN TYROSINE KINASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283432-A1 | DERIVATIVES OF MACROCYCLIC N-ARYL-TRICYCLOPYRIMIDINE-2-AMINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK | JAK2, JAK3, JAK1 | MAOB 3950/4885CYP19A1 4286/4885MAOA 4159/4885 |
| US-10323043-B2 | Derivatives of macrocyclic N-aryl-tricyclopyrimidine-2-amine polyethers as inhibitors of FTL3 and JAK | JAK2, JAK3, JAK1 | MAOB 3950/4885CYP19A1 4286/4885MAOA 4159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.